Abstract: Objective  To observe the influence of tyrosine kinase inhibitors (TKIs) on the proliferation,  efficacy and adverse reactions (AEs) of CD19 CART cells in refractory/relapsed Ph+ acute lymphoblastic leukemia (Ph+ ALL).Methods  Ten patients with refractory/relapsed Ph+ ALL (TKIs group) and 16 patients with refractory/relapsed Phnegative BALL (nonTKIs group) were collected,  and TKIs group was given TKIs orally. CD19 CART cells were detected  in peripheral blood at 0,  4,  7,  14,  21 and 28  days after infusion, and the clinical efficacy and AEs of  two groups  were analyzed. Results  The peak value of CD19 CART cells in peripheral blood in TKIs group was higher than that in nonTKIs group,  with statistically  significant differences between the two groups (P=0.0037). There were no statistically  significant differences in cytokine  peak, cytokine release syndrome (CRS) grading,  the complete response (CR) rate at day 14,  overall survival (OS) rate  and diseasefree survival (DFS)  rate  between the two groups (P>0.05). Conclusion  TKIs promoted the proliferation of CD19 CART cells in refractory/relapsed Ph+ ALL,  without inhibiting the clinical efficacy of CD19 CART cells and aggravating AEs,  which showed positively shortterm and longterm effects.

Key words: leukemia, , lymphoblastic; , chimeric antigen receptor, tyrosine kinase inhibitors; , philadelphia chromosome positive